Table 4.
Outcomes in relation to specific adverse events in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial[82]
| Outcome measure | AE | Number of AEs (yes versus no AE) | Hazard ratio | 95% CI | P value |
|---|---|---|---|---|---|
| DFS |
VMS |
249 versus 837 |
0.731 |
0.618-0.866 |
<0.001 |
| |
MSAE |
239 versus 847 |
0.826 |
0.694-0.982 |
0.030 |
| |
VVS |
89 versus 997 |
0.769 |
0.585-1.01 |
0.058 |
| |
Overall |
418 versus 668 |
0.735 |
0.632-0.855 |
<0.001 |
| OS |
VMS |
147 versus 617 |
0.583 |
0.424-0.803 |
0.001 |
| |
MSAE |
151 versus 613 |
0.811 |
0.654-1.005 |
0.055 |
| |
VVS |
51 versus 713 |
0.570 |
0.391-0.831 |
0.003 |
| |
Overall |
268 versus 496 |
0.680 |
0.565-0.819 |
<0.001 |
| DM |
VMS |
165 versus 490 |
0.813 |
0.664-0.996 |
0.046 |
| |
MSAE |
138 versus 517 |
0.749 |
0.601-0.934 |
0.010 |
| |
VVS |
54 versus 601 |
0.687 |
0.435-1.085 |
0.107 |
| Overall | 261 versus 394 | 0.783 | 0.651-0.942 | 0.010 |
AE, adverse event; CI, confidence interval; DFS, disease-free survival; DM, distant metastases; MSAE, musculoskeletal adverse event; OS, overall survival; VMS, vasomotor symptoms; VVS, vulvovaginal symptoms.